SMMT Summit TherapeuticsWatchlist
About Summit Therapeutics Company
Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.
ESGL, HNRA and SMX Among Pre-market Losers
Earnings Call: Summit Therapeutics Highlights Progress in Ivonescimab Trials and Financial Growth
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
Enrollment Initiated in Second Phase III Clinical Study for Ivonescimab, HARMONi-3Continuing Enrollment of HARMONi Phase III Study, with Enrollment Completion Expected in Second Half of 2024Manmeet S.